The market implications of this study are significant for BioNTech SE, as successful outcomes could enhance its stock performance and investor confidence. The study’s progress and results could also ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed ...

The settlement ends US mRNA patent disputes involving COVID-19 and influenza vaccines, while positioning GSK for additional ...

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Biontech Se ADR (BNTX-Q) from The Globe and Mail including charting and trades.

The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results ...

BioNTech also laid off 63 employees in June in conjunction with the discontinuation of its cell therapy manufacturing ...

As part of a "strategic alignment" of its pipeline, BioNTech is laying off 90 workers in R&D and corporate roles across two sites in Maryland and Massachusetts, a spokesperson told Fierce. | As part ...

Clear Street raised the firm’s price target on BioNTech (BNTX) to $185 from $181 and keeps a Buy rating on the shares after updating the firm’s model to a year-end 2026 valuation following the company ...

Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive surprises than negative ones.

Why it matters: In addition to ongoing clinical trial progress for BNT327, BioNTech was active on the business development ...